MTOR and prostate cancer: In prostate cancer, microRNA-99a suppresses the expression of prostate-specific antigens and prostate cancer cell proliferation by interfering with the expression of two chromatin remodeling factors, SMARCA5 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5) and SMARCD1 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 1), and the growth regulatory kinase mTOR (mammalian target of rapamycin) [29].